PMID- 31030505
OWN - NLM
STAT- MEDLINE
DCOM- 20190906
LR  - 20200205
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 20
IP  - 4
DP  - 2019 Apr 29
TI  - Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ 
      Hybridization for Bladder Cancer in a Single Community of Japanese Hospital 
      Patients.
PG  - 1271-1273
AB  - Objective: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on 
      multicolor fluorescence in situ hybridization (FISH). It has been used 
      successfully in the USA following its Food and Drug Administration approval in 
      2001. However, the technology was not approved for use in Japan until 2017. 
      Cystoscopy and urine cytology are the most frequently used examinations to detect 
      bladder cancer in Japan, and there are only a few reports regarding the 
      performance of UroVysion. Therefore, the aim of this study is to examine the 
      diagnostic accuracy of UroVysion FISH in Japanese patients whose tumors are 
      detected by cystoscopy before transurethral resection of bladder tumor (TURBT). 
      Methods: From April 2018 to July 2018, a total of 40 patients who were diagnosed 
      as having bladder tumors by cystoscopy, and therefore underwent TURBT were 
      registered in this study. One day before TURBT, urine cytology and UroVysion FISH 
      were used in order to compare the accuracy with which they could detect bladder 
      carcinoma, as confirmed by pathological results of TURBT. Results: The 
      pathological results of TURBT showed urothelial carcinoma in 33 cases. Urine 
      cytology showed positive results for 0 cases (0%), suspicious results for 10 
      cases (30.3%), and negative results for 23 cases (69.7%). On the other hand, 
      UroVysion FISH indicated 9 positive cases (27.3%) and 24 negative cases (72.7%). 
      There were 19 cases of urothelial carcinoma (57.6%) that were not detected by 
      either method. Conclusion: We conclude that UroVysion FISH alone is insufficient 
      to detect bladder cancer and that cystoscopy is essential for the optimum 
      detection or follow up of bladder cancer cases in our hospital.
CI  - Creative Commons Attribution License
FAU - Nagai, Takashi
AU  - Nagai T
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Okamura, Takehiko
AU  - Okamura T
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Yanase, Takahiro
AU  - Yanase T
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Chaya, Ryosuke
AU  - Chaya R
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Moritoki, Yoshinobu
AU  - Moritoki Y
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Kobayashi, Daichi
AU  - Kobayashi D
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Akita, Hidetoshi
AU  - Akita H
AD  - Department of Urology, Anjo Kosei Hospital, 28 Higashihirokute, Anjo-cho, Anjo, 
      Japan.Email: hiko2546@sf.commufa.jp
FAU - Yasui, Takahiro
AU  - Yasui T
AD  - Department of Nephro-Urology, Nagoya City University Graduate School of Medical 
      Sciences, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190429
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cystoscopy/*methods
MH  - Cytodiagnosis/*methods
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Reagent Kits, Diagnostic
MH  - Urinary Bladder Neoplasms/*diagnosis
MH  - Urine/*chemistry/cytology
PMC - PMC6948889
OTO - NOTNLM
OT  - *Urinary bladder carcinoma
OT  - *cystoscopy
OT  - *FISH
OT  - *cytology
COIS- The authors declare no conflicts of interest.
EDAT- 2019/04/30 06:00
MHDA- 2019/09/07 06:00
PMCR- 2019/03/01
CRDT- 2019/04/30 06:00
PHST- 2019/04/30 06:00 [entrez]
PHST- 2019/04/30 06:00 [pubmed]
PHST- 2019/09/07 06:00 [medline]
PHST- 2019/03/01 00:00 [pmc-release]
AID - 10.31557/APJCP.2019.20.4.1271 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1271-1273. doi: 
      10.31557/APJCP.2019.20.4.1271.